base metals investing Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
base metals investing Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
base metals investing Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer
